Vitamin D, Cancer Risk, and Mortality

Advances in Food and Nutrition Research

Volumn 75, Issue , 2015, Pages 1-52

  Tagliabue, Elena ^a   Raimondi, Sara ^a   Gandini, Sara ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

25(OH)D; Cancer incidence; Cancer mortality; Overall mortality; Vitamin D; Vitamin D receptor; Vitamin D binding protein

Indexed keywords

25-HYDROXYVITAMIN D; CALCITRIOL RECEPTOR; VITAMIN D; VITAMIN D BINDING PROTEIN;

ANALOGS AND DERIVATIVES; DIET SUPPLEMENTATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; MORTALITY; NEOPLASM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SUNLIGHT;

DIETARY SUPPLEMENTS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MORTALITY; NEOPLASMS; POLYMORPHISM, GENETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CALCITRIOL; RISK FACTORS; SUNLIGHT; VITAMIN D; VITAMIN D-BINDING PROTEIN;

EID: 84940714188     PISSN: 10434526     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.afnr.2015.06.003     Document Type: Chapter

References (216)

1. Abbas S., Chang-Claude J., Linseisen J. Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a german case-control study. International Journal of Cancer 2009, 124(1):250-255.
2. Abbas S., Linseisen J., Slanger T., Kropp S., Mutschelknauss E.J., Flesch-Janys D., et al. The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status. Cancer Epidemiology, Biomarkers & Prevention 2008, 17(6):1339-1343.
3. Ahn J., Yu K., Stolzenberg-Solomon R., Simon K.C., McCullough M.L., Gallicchio L., et al. Genome-wide association study of circulating vitamin D levels. Human Molecular Genetics 2010, 19(13):2739-2745.
4. Anderson L.N., Cotterchio M., Cole D.E., Knight J.A. Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidemiology, Biomarkers & Prevention 2011, 20(8):1708-1717.
5. Anderson L.N., Cotterchio M., Knight J.A., Borgida A., Gallinger S., Cleary S.P. Genetic variants in vitamin D pathway genes and risk of pancreas cancer; results from a population-based case-control study in Ontario, Canada. PLoS One 2013, 8(6):e66768.
6. Anderson G.L., Manson J., Wallace R., Lund B., Hall D., Davis S., et al. Implementation of the women's health initiative study design. Annals of Epidemiology 2003, 13(9 Suppl.):S5-S17.
7. Anic G.M., Thompson R.C., Nabors L.B., Olson J.J., Browning J.E., Madden M.H., et al. An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome. Cancer Causes & Control 2012, 23(9):1443-1449.
8. Anic G.M., Weinstein S.J., Mondul A.M., Mannisto S., Albanes D. Serum vitamin D, vitamin D binding protein, and risk of colorectal cancer. PLoS One 2014, 9(7):e102966.
9. Arai H., Miyamoto K.I., Yoshida M., Yamamoto H., Taketani Y., Morita K., et al. The polymorphism in the caudal-related homeodomain protein cdx-2 binding element in the human vitamin D receptor gene. Journal of Bone and Mineral Research 2001, 16(7):1256-1264.
10. Arjumand W., Ahmad S.T., Seth A., Saini A.K., Sultana S. Vitamin D receptor FokI and BsmI gene polymorphism and its association with grade and stage of renal cell carcinoma in North Indian population. Tumour Biology 2012, 33(1):23-31.
11. Armstrong B. How sun exposure causes skin cancer: An epidemiological perspective. Prevention of skin cancer 2004, 89-116. Kluwer Academic Publishers, Dordrecht, Netherlands. D. Hill, D. English, R. Elwood, J. Mark (Eds.).
12. Autier P., Boniol M., Pizot C., Mullie P. Vitamin D status and ill health: A systematic review. The Lancet Diabetes & Endocrinology 2014, 2(1):76-89.
13. Autier P., Gandini S., Mullie P. A systematic review: Influence of vitamin D supplementation on serum 25-hydroxyvitamin D concentration. The Journal of Clinical Endocrinology and Metabolism 2012, 97(8):2606-2613.
14. Avenell A., MacLennan G.S., Jenkinson D.J., McPherson G.C., McDonald A.M., Pant P.R., et al. Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trial). The Journal of Clinical Endocrinology and Metabolism 2012, 97(2):614-622.
15. Bai Y.H., Lu H., Hong D., Lin C.C., Yu Z., Chen B.C. Vitamin D receptor gene polymorphisms and colorectal cancer risk: A systematic meta-analysis. World Journal of Gastroenterology 2012, 18(14):1672-1679.
16. Bai Y., Yu Y., Yu B., Ge J., Ji J., Lu H., et al. Association of vitamin D receptor polymorphisms with the risk of prostate cancer in the Han population of Southern China. BMC Medical Genetics 2009, 10. 125-2350-10-125.
17. Barroso E., Fernandez L.P., Milne R.L., Pita G., Sendagorta E., Floristan U., et al. Genetic analysis of the vitamin D receptor gene in two epithelial cancers: Melanoma and breast cancer case-control studies. BMC Cancer 2008, 8:385. 385-2407-8-385.
18. Bentley R.W., Keown D.A., Gearry R.B., Cameron V.A., Keenan J., Roberts R.L., et al. Vitamin D receptor polymorphisms in colorectal cancer in New Zealand: An association study. The New Zealand Medical Journal 2012, 125(1356):47-51.
19. Bhaskaran K., Douglas I., Forbes H., dos-Santos-Silva I., Leon D.A., Smeeth L. Body-mass index and risk of 22 specific cancers: A population-based cohort study of 5.24 million UK adults. Lancet 2014, 384(9945):755-765.
20. Bikle D.D., Gee E. Free, and not total, 1,25-dihydroxyvitamin D regulates 25-hydroxyvitamin D metabolism by keratinocytes. Endocrinology 1989, 124(2):649-654.
21. Bolland M.J., Grey A., Gamble G.D., Reid I.R. Calcium and vitamin D supplements and health outcomes: A reanalysis of the Women's Health Initiative (WHI) limited-access data set. American Journal Of Clinical Nutrition 2011, 94(4):1144-1149.
22. Bouillon R., Carmeliet G., Verlinden L., van Etten E., Verstuyf A., Luderer H.F., et al. Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocrine Reviews 2008, 29(6):726-776.
23. Brunner R.L., Wactawski-Wende J., Caan B.J., Cochrane B.B., Chlebowski R.T., Gass M.L., et al. The effect of calcium plus vitamin D on risk for invasive cancer: Results of the women's health initiative (WHI) calcium plus vitamin D randomized clinical trial. Nutrition and Cancer 2011, 63(6):827-841.
24. Buyru N., Tezol A., Yosunkaya-Fenerci E., Dalay N. Vitamin D receptor gene polymorphisms in breast cancer. Experimental & Molecular Medicine 2003, 35(6):550-555.
25. Caini S., Boniol M., Tosti G., Magi S., Medri M., Stanganelli I., et al. Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: A comprehensive review and meta-analysis. European Journal of Cancer (Oxford, England: 1990) 2014, 50(15):2649-2658.
26. Carter G.D. Accuracy of 25-hydroxyvitamin D assays: Confronting the issues. Current Drug Targets 2011, 12(1):19-28.
27. Cawthon P.M., Parimi N., Barrett-Connor E., Laughlin G.A., Ensrud K.E., Hoffman A.R., et al. Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men. The Journal of Clinical Endocrinology and Metabolism 2010, 95(10):4625-4634.
28. Chen Y., Liu W., Sun T., Huang Y., Wang Y., Deb D.K., et al. 1,25-dihydroxyvitamin D promotes negative feedback regulation of TLR signaling via targeting microRNA-155-SOCS1 in macrophages. Journal of Immunology (Baltimore, Maryland: 1950) 2013, 190(7):3687-3695.
29. Chlebowski R.T., Johnson K.C., Kooperberg C., Pettinger M., Wactawski-Wende J., Rohan T., et al. Calcium plus vitamin D supplementation and the risk of breast cancer. Journal of the National Cancer Institute 2008, 100(22):1581-1591.
30. Chowdhury R., Kunutsor S., Vitezova A., Oliver-Williams C., Chowdhury S., Kiefte-de-Jong J.C., et al. Vitamin D and risk of cause specific death: Systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ (Clinical Research Ed.) 2014, 348:g1903.
31. Cicek M.S., Liu X., Schumacher F.R., Casey G., Witte J.S. Vitamin D receptor genotypes/haplotypes and prostate cancer risk. Cancer Epidemiology, Biomarkers & Prevention 2006, 15(12):2549-2552.
32. Clendenen T.V., Arslan A.A., Koenig K.L., Enquist K., Wirgin I., Agren A., et al. Vitamin D receptor polymorphisms and risk of epithelial ovarian cancer. Cancer Letters 2008, 260(1-2):209-215.
33. Colston K., Colston M.J., Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: The presence of receptors and inhibition of cell growth in culture. Endocrinology 1981, 108(3):1083-1086.
34. Curran J.E., Vaughan T., Lea R.A., Weinstein S.R., Morrison N.A., Griffiths L.R. Association of a vitamin D receptor polymorphism with sporadic breast cancer development. International Journal of Cancer 1999, 83(6):723-726.
35. DeLuca H.F. Overview of general physiologic features and functions of vitamin D. The American Journal of Clinical Nutrition 2004, 80(6 Suppl.):1689S-1696S.
36. Denzer N., Vogt T., Reichrath J. Vitamin D receptor (VDR) polymorphisms and skin cancer: A systematic review. Dermato-Endocrinology 2011, 3(3):205-210.
37. Doorenbos C.R., van den Born J., Navis G., de Borst M.H. Possible renoprotection by vitamin D in chronic renal disease: Beyond mineral metabolism. Nature Reviews Nephrology 2009, 5(12):691-700.
38. Dorjgochoo T., Delahanty R., Lu W., Long J., Cai Q., Zheng Y., et al. Common genetic variants in the vitamin D pathway including genome-wide associated variants are not associated with breast cancer risk among chinese women. Cancer Epidemiology, Biomarkers & Prevention 2011, 20(10):2313-2316.
39. Drake M.T., Maurer M.J., Link B.K., Habermann T.M., Ansell S.M., Micallef I.N., et al. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. Journal of Clinical Oncology 2010, 28(27):4191-4198.
40. Durrin L.K., Haile R.W., Ingles S.A., Coetzee G.A. Vitamin D receptor 3'-untranslated region polymorphisms: Lack of effect on mRNA stability. Biochimica et Biophysica Acta 1999, 1453(3):311-320.
41. Durup D., Jorgensen H.L., Christensen J., Schwarz P., Heegaard A.M., Lind B. A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: The CopD study. The Journal of Clinical Endocrinology and Metabolism 2012, 97(8):2644-2652.
42. Dusso A.S., Brown A.J., Slatopolsky E. Vitamin D. American Journal of Physiology. Renal Physiology 2005, 289(1):F8-F28.
43. Eaton C.B., Young A., Allison M.A., Robinson J., Martin L.W., Kuller L.H., et al. Prospective association of vitamin D concentrations with mortality in postmenopausal women: Results from the women's health initiative (WHI). The American Journal of Clinical Nutrition 2011, 94(6):1471-1478.
44. Eisman J.A., Barkla D.H., Tutton P.J. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Research 1987, 47(1):21-25.
45. El Ghissassi F., Baan R., Straif K., Grosse Y., Secretan B., Bouvard V., et al. A review of human carcinogens-Part D: Radiation. The Lancet Oncology 2009, 10(8):751-752.
46. Elamin M.B., Abu Elnour N.O., Elamin K.B., Fatourechi M.M., Alkatib A.A., Almandoz J.P., et al. Vitamin D and cardiovascular outcomes: A systematic review and meta-analysis. The Journal of Clinical Endocrinology and Metabolism 2011, 96(7):1931-1942.
47. Engelman C.D., Fingerlin T.E., Langefeld C.D., Hicks P.J., Rich S.S., Wagenknecht L.E., et al. Genetic and environmental determinants of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels in hispanic and African Americans. The Journal of Clinical Endocrinology and Metabolism 2008, 93(9):3381-3388.
48. Evans S.R., Houghton A.M., Schumaker L., Brenner R.V., Buras R.R., Davoodi F., et al. Vitamin D receptor and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. The Journal of Surgical Research 1996, 61(1):127-133.
49. Fang F., Kasperzyk J.L., Shui I., Hendrickson W., Hollis B.W., Fall K., et al. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS One 2011, 6(4):e18625.
50. Farrell C.J., Martin S., McWhinney B., Straub I., Williams P., Herrmann M. State-of-the-art vitamin D assays: A comparison of automated immunoassays with liquid chromatography-tandem mass spectrometry methods. Clinical Chemistry 2012, 58(3):531-542.
51. Fedirko V., Riboli E., Tjonneland A., Ferrari P., Olsen A., Bueno-de-Mesquita H.B., et al. Prediagnostic 25-hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European populations. Cancer Epidemiology, Biomarkers & Prevention 2012, 21(4):582-593.
52. Fiscella K., Winters P., Tancredi D., Hendren S., Franks P. Racial disparity in death from colorectal cancer: Does vitamin D deficiency contribute?. Cancer 2011, 117(5):1061-1069.
53. Flohil S.C., de Vries E., van Meurs J.B., Fang Y., Stricker B.H., Uitterlinden A.G., et al. Vitamin D-binding protein polymorphisms are not associated with development of (multiple) basal cell carcinomas. Experimental Dermatology 2010, 19(12):1103-1105.
54. Flugge J., Krusekopf S., Goldammer M., Osswald E., Terhalle W., Malzahn U., et al. Vitamin D receptor haplotypes protect against development of colorectal cancer. European Journal of Clinical Pharmacology 2007, 63(11):997-1005.
55. Freedman D., Fuhrman B., Graubard B.I., Chang S.C. Vitamin D and cancer mortality. Cancer Epidemiology, Biomarkers & Prevention 2009, 18(1):359. author reply 359-360.
56. Freedman D.M., Looker A.C., Abnet C.C., Linet M.S., Graubard B.I. Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer Research 2010, 70(21):8587-8597.
57. Freedman D.M., Looker A.C., Chang S.C., Graubard B.I. Prospective study of serum vitamin D and cancer mortality in the United States. Journal of the National Cancer Institute 2007, 99(21):1594-1602.
58. Fu B., Wang H., Wang J., Barouhas I., Liu W., Shuboy A., et al. Epigenetic regulation of BMP2 by 1,25-dihydroxyvitamin D3 through DNA methylation and histone modification. PLoS One 2013, 8(4):e61423.
59. Fuhrman B.J., Freedman D.M., Bhatti P., Doody M.M., Fu Y.P., Chang S.C., et al. Sunlight, polymorphisms of vitamin D-related genes and risk of breast cancer. Anticancer Research 2013, 33(2):543-551.
60. Gandini S., Boniol M., Haukka J., Byrnes G., Cox B., Sneyd M.J., et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. International Journal of Cancer 2011, 128(6):1414-1424.
61. Gandini S., Gnagnarella P., Serrano D., Pasquali E., Raimondi S. Vitamin D receptor polymorphisms and cancer. Advances in Experimental Medicine and Biology 2014, 810:69-105.
62. Gandini S., Raimondi S., Gnagnarella P., Dore J.F., Maisonneuve P., Testori A. Vitamin D and skin cancer: A meta-analysis. European Journal of Cancer (Oxford, England: 1990) 2009, 45(4):634-641.
63. Gandini S., Sera F., Cattaruzza M.S., Pasquini P., Picconi O., Boyle P., et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. European Journal of Cancer (Oxford, England: 1990) 2005, 41(1):45-60.
64. Gapska P., Scott R.J., Serrano-Fernandez P., Huzarski T., Byrski T., Kladny J., et al. Vitamin D receptor variants and breast cancer risk in the polish population. Breast Cancer Research and Treatment 2009, 115(3):629-633.
65. Garland C.F., Comstock G.W., Garland F.C., Helsing K.J., Shaw E.K., Gorham E.D. Serum 25-hydroxyvitamin D and colon cancer: Eight-year prospective study. Lancet 1989, 2(8673):1176-1178.
66. Garland C.F., Garland F.C., Gorham E.D., Lipkin M., Newmark H., Mohr S.B., et al. The role of vitamin D in cancer prevention. American Journal of Public Health 2006, 96(2):252-261.
67. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: A review (United States). Cancer Causes & Control 2005, 16(2):83-95.
68. Giovannucci E., Liu Y., Rimm E.B., Hollis B.W., Fuchs C.S., Stampfer M.J., et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. Journal of the National Cancer Institute 2006, 98(7):451-459.
69. Gnagnarella P., Pasquali E., Serrano D., Raimondi S., Disalvatore D., Gandini S. Vitamin D receptor polymorphism FokI and cancer risk: A comprehensive meta-analysis. Carcinogenesis 2014, 35(9):1913-1919.
70. Goodwin P.J., Ennis M., Pritchard K.I., Koo J., Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. Journal of Clinical Oncology 2009, 27(23):3757-3763.
71. Grant D.J., Hoyo C., Akushevich L., Iversen E.S., Whitaker R., Marks J., et al. Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women. Gynecologic Oncology 2013, 129(1):173-178.
72. Grimes D.S. Are statins analogues of vitamin D?. Lancet 2006, 368(9529):83-86.
73. Gross C., Krishnan A.V., Malloy P.J., Eccleshall T.R., Zhao X.Y., Feldman D. The vitamin D receptor gene start codon polymorphism: A functional analysis of FokI variants. Journal of Bone and Mineral Research 1998, 13(11):1691-1699.
74. Gu H., Wang X., Zheng L., Tang W., Dong C., Wang L., et al. Vitamin D receptor gene polymorphisms and esophageal cancer risk in a Chinese population: A negative study. Medical Oncology (Northwood, London, England) 2014, 31(2). 827-013-0827-x. Epub 2014 Jan 1.
75. Gugatschka M., Kiesler K., Obermayer-Pietsch B., Groselj-Strele A., Griesbacher A., Friedrich G. Vitamin D status is associated with disease-free survival and overall survival time in patients with squamous cell carcinoma of the upper aerodigestive tract. European Archives of Oto-Rhino-Laryngology 2011, 268(8):1201-1204.
76. Gunduz M., Cacina C., Toptas B., Yaylim-Eraltan I., Tekand Y., Isbir T. Association of vitamin D receptor gene polymorphisms with colon cancer. Genetic Testing and Molecular Biomarkers 2012, 16(9):1058-1061.
77. Guy M., Lowe L.C., Bretherton-Watt D., Mansi J.L., Peckitt C., Bliss J., et al. Vitamin D receptor gene polymorphisms and breast cancer risk. Clinical Cancer Research 2004, 10(16):5472-5481.
78. Han J., Colditz G.A., Hunter D.J. Risk factors for skin cancers: A nested case-control study within the nurses' health study. International Journal of Epidemiology 2006, 35(6):1514-1521.
79. Han J., Colditz G.A., Hunter D.J. Polymorphisms in the MTHFR and VDR genes and skin cancer risk. Carcinogenesis 2007, 28(2):390-397.
80. Hansen C.M., Madsen M.W., Arensbak B., Skak-Nielsen T., Latini S., Binderup L. Down-regulation of laminin-binding integrins by 1 alpha,25-dihydroxyvitamin D3 in human melanoma cells in vitro. Cell Adhesion and Communication 1998, 5(2):109-120.
81. Heist R.S., Zhou W., Wang Z., Liu G., Neuberg D., Su L., et al. Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. Journal of Clinical Oncology 2008, 26(34):5596-5602.
82. Hewison M. An update on vitamin D and human immunity. Clinical Endocrinology 2012, 76(3):315-325.
83. Hine T.J., Roberts N.B. Seasonal variation in serum 25-hydroxy vitamin D3 does not affect 1,25-dihydroxy vitamin D. Annals of Clinical Biochemistry 1994, 31(Pt. 1):31-34.
84. Hiraki L.T., Qu C., Hutter C.M., Baron J.A., Berndt S.I., Bezieau S., et al. Genetic predictors of circulating 25-hydroxyvitamin D and risk of colorectal cancer. Cancer Epidemiology, Biomarkers & Prevention 2013, 22(11):2037-2046.
85. Holick M.F. Vitamin D and bone health. The Journal of Nutrition 1996, 126(4 Suppl.):1159S-1164S.
86. Holick M.F. Vitamin D: The underappreciated D-lightful hormone that is important for skeletal and cellular health. Current Opinion in Endocrinology, Diabetes, and Obesity 2002, 9(1):87-98.
87. Holick M.F. Vitamin D deficiency. The New England Journal of Medicine 2007, 357(3):266-281.
88. Hollis B.W. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: Implications for establishing a new effective dietary intake recommendation for vitamin D. The Journal of Nutrition 2005, 135(2):317-322.
89. Holt S.K., Kwon E.M., Peters U., Ostrander E.A., Stanford J.L. Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiology, Biomarkers & Prevention 2009, 18(6):1929-1933.
90. Huang J., Huang J., Ma Y., Wang H., Yang J., Xiong T., et al. The cdx-2 polymorphism in the VDR gene is associated with increased risk of cancer: A meta-analysis. Molecular Biology Reports 2013, 40(7):4219-4225.
91. Hughes D.J., Hlavata I., Soucek P., Pardini B., Naccarati A., Vodickova L., et al. Variation in the vitamin D receptor gene is not associated with risk of colorectal cancer in the Czech Republic. Journal of Gastrointestinal Cancer 2011, 42(3):149-154.
92. Hutchinson M.S., Grimnes G., Joakimsen R.M., Figenschau Y., Jorde R. Low serum 25-hydroxyvitamin D levels are associated with increased all-cause mortality risk in a general population: The tromso study. European Journal of Endocrinology/European Federation of Endocrine Societies 2010, 162(5):935-942.
93. IARC IARC monographs on the evaluation of carcinogenic risks to humans. Solar and ultraviolet radiation. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans/World Health Organization, International Agency for Research on Cancer 1992, 55:1-316.
94. IARC Vitamin D and cancer. IARC Working Group Reports 2008, International Agency for Research on Cancer, Lyon, France.
95. Ingles S.A., Haile R.W., Henderson B.E., Kolonel L.N., Nakaichi G., Shi C.Y., et al. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: Implications for association studies. Cancer Epidemiology, Biomarkers & Prevention 1997, 6(2):93-98.
96. Jacobs E.T., Thomson C.A., Flatt S.W., Al-Delaimy W.K., Hibler E.A., Jones L.A., et al. Vitamin D and breast cancer recurrence in the women's healthy eating and living (WHEL) study. The American Journal of Clinical Nutrition 2011, 93(1):108-117.
97. Jenab M., McKay J., Bueno-de-Mesquita H.B., van Duijnhoven F.J., Ferrari P., Slimani N., et al. Vitamin D receptor and calcium sensing receptor polymorphisms and the risk of colorectal cancer in european populations. Cancer Epidemiology, Biomarkers & Prevention 2009, 18(9):2485-2491.
98. John E.M., Schwartz G.G., Koo J., Van Den Berg D., Ingles S.A. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Research 2005, 65(12):5470-5479.
99. Karami S., Andreotti G., Koutros S., Barry K.H., Moore L.E., Han S., et al. Pesticide exposure and inherited variants in vitamin D pathway genes in relation to prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 2013, 22(9):1557-1566.
100. Karami S., Brennan P., Hung R.J., Boffetta P., Toro J., Wilson R.T., et al. Vitamin D receptor polymorphisms and renal cancer risk in central and eastern Europe. Journal of Toxicology and Environmental Health, Part A 2008, 71(6):367-372.
101. Kim Y., Je Y. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: A meta-analysis. British Journal of Cancer 2014, 110(11):2772-2784.
102. Kostner K., Denzer N., Koreng M., Reichrath S., Graber S., Klein R., et al. Association of genetic variants of the vitamin D receptor (VDR) with cutaneous squamous cell carcinomas (SCC) and basal cell carcinomas (BCC): A pilot study in a german population. Anticancer Research 2012, 32(1):327-333.
103. Kostner K., Denzer N., Muller C.S., Klein R., Tilgen W., Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: A review of the literature. Anticancer Research 2009, 29(9):3511-3536.
104. Krause R., Schober-Halstenberg H.J., Edenharter G., Haas K., Roth H.J., Frei U. Vitamin D status and mortality of german hemodialysis patients. Anticancer Research 2012, 32(1):391-395.
105. Kricker A., Armstrong B. Does sunlight have a beneficial influence on certain cancers?. Progress in Biophysics and Molecular Biology 2006, 92(1):132-139.
106. Lappe J.M., Travers-Gustafson D., Davies K.M., Recker R.R., Heaney R.P. Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. The American Journal of Clinical Nutrition 2007, 85(6):1586-1591.
107. Lauridsen A.L., Vestergaard P., Hermann A.P., Brot C., Heickendorff L., Mosekilde L., et al. Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of gc (vitamin D-binding protein): A cross-sectional study on 595 early postmenopausal women. Calcified Tissue International 2005, 77(1):15-22.
108. Lesiak A., Norval M., Wodz-Naskiewicz K., Pawliczak R., Rogowski-Tylman M., Sysa-Jedrzejowska A., et al. An enhanced risk of basal cell carcinoma is associated with particular polymorphisms in the VDR and MTHFR genes. Experimental Dermatology 2011, 20(10):800-804.
109. Li C., Li Y., Gao L.B., Wang Y.Y., Zhou B., Lv M.L., et al. Vitamin D receptor gene polymorphisms and the risk of colorectal cancer in a chinese population. Digestive Diseases and Sciences 2009, 54(3):634-639.
110. Li H., Stampfer M.J., Hollis J.B., Mucci L.A., Gaziano J.M., Hunter D., et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Medicine 2007, 4(3):e103.
111. Li L., Wu B., Yang L., Yin G., Wei W., Sui S., et al. Association of vitamin D receptor gene polymorphisms with pancreatic cancer: A pilot study in a north China population. Oncology Letters 2013, 5(5):1731-1735.
112. Liao Y., Huang J.L., Qiu M.X., Ma Z.W. Impact of serum vitamin D level on risk of bladder cancer: A systemic review and meta-analysis. Tumour Biology 2015, 36(3):1567-1572.
113. Lim H.S., Roychoudhuri R., Peto J., Schwartz G., Baade P., Moller H. Cancer survival is dependent on season of diagnosis and sunlight exposure. International Journal of Cancer 2006, 119(7):1530-1536.
114. Liu J.J., Bertrand K.A., Karageorgi S., Giovannucci E., Hankinson S.E., Rosner B., et al. Prospective analysis of vitamin D and endometrial cancer risk. Annals of Oncology 2013, 24(3):687-692.
115. Liu Z., Calderon J.I., Zhang Z., Sturgis E.M., Spitz M.R., Wei Q. Polymorphisms of vitamin D receptor gene protect against the risk of head and neck cancer. Pharmacogenetics and Genomics 2005, 15(3):159-165.
116. Lurie G., Wilkens L.R., Thompson P.J., Carney M.E., Palmieri R.T., Pharoah P.D., et al. Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: Pooled analysis in five studies within the ovarian cancer association consortium. International Journal of Cancer 2011, 128(4):936-943.
117. Lurie G., Wilkens L.R., Thompson P.J., McDuffie K.E., Carney M.E., Terada K.Y., et al. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiology, Biomarkers & Prevention 2007, 16(12):2566-2571.
118. Mahmoudi T., Karimi K., Mohebbi S.R., Fatemi S.R., Zali M.R. Start codon FokI and intron 8 BsmI variants in the vitamin D receptor gene and susceptibility to colorectal cancer. Molecular Biology Reports 2011, 38(7):4765-4770.
119. Maki K.C., Rubin M.R., Wong L.G., McManus J.F., Jensen C.D., Lawless A. Effects of vitamin D supplementation on 25-hydroxyvitamin D, high-density lipoprotein cholesterol, and other cardiovascular disease risk markers in subjects with elevated waist circumference. International Journal of Food Sciences and Nutrition 2011, 62(4):318-327.
120. Manson J.E., Bassuk S.S., Lee I.M., Cook N.R., Albert M.A., Gordon D., et al. The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials 2012, 33(1):159-171.
121. McCullough M.L., Stevens V.L., Diver W.R., Feigelson H.S., Rodriguez C., Bostick R.M., et al. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: A nested case-control study. Breast Cancer Research 2007, 9(1):R9.
122. McKay J.D., McCullough M.L., Ziegler R.G., Kraft P., Saltzman B.S., Riboli E., et al. Vitamin D receptor polymorphisms and breast cancer risk: Results from the national cancer institute breast and prostate cancer cohort consortium. Cancer Epidemiology, Biomarkers & Prevention 2009, 18(1):297-305.
123. Melamed M.L., Michos E.D., Post W., Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Archives of Internal Medicine 2008, 168(15):1629-1637.
124. Meyer F., Liu G., Douville P., Samson E., Xu W., Adjei A., et al. Dietary vitamin D intake and serum 25-hydroxyvitamin D level in relation to disease outcomes in head and neck cancer patients. International Journal of Cancer 2011, 128(7):1741-1746.
125. Mezawa H., Sugiura T., Watanabe M., Norizoe C., Takahashi D., Shimojima A., et al. Serum vitamin D levels and survival of patients with colorectal cancer: Post-hoc analysis of a prospective cohort study. BMC Cancer 2010, 10. 347-2407-10-347.
126. Michaelsson K., Baron J.A., Snellman G., Gedeborg R., Byberg L., Sundstrom J., et al. Plasma vitamin D and mortality in older men: A community-based prospective cohort study. The American Journal of Clinical Nutrition 2010, 92(4):841-848.
127. Mikhak B., Hunter D.J., Spiegelman D., Platz E.A., Hollis B.W., Giovannucci E. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. The Prostate 2007, 67(9):911-923.
128. Mittal R.D., Manchanda P.K., Bhat S., Bid H.K. Association of vitamin-D receptor (fok-I) gene polymorphism with bladder cancer in an indian population. BJU International 2007, 99(4):933-937.
129. Moan J., Porojnicu A.C., Dahlback A., Setlow R.B. Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(2):668-673.
130. Mocellin S., Nitti D. Vitamin D receptor polymorphisms and the risk of cutaneous melanoma: A systematic review and meta-analysis. Cancer 2008, 113(9):2398-2407.
131. Mondul A.M., Shui I.M., Yu K., Travis R.C., Stevens V.L., Campa D., et al. Genetic variation in the vitamin D pathway in relation to risk of prostate cancer-Results from the breast and prostate cancer cohort consortium. Cancer Epidemiology, Biomarkers & Prevention 2013, 22(4):688-696.
132. Mondul A.M., Weinstein S.J., Horst R.L., Purdue M., Albanes D. Serum vitamin D and risk of bladder cancer in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Cancer Epidemiology, Biomarkers & Prevention 2012, 21(7):1222-1225.
133. Mondul A.M., Weinstein S.J., Moy K.A., Mannisto S., Albanes D. Vitamin D-binding protein, circulating vitamin D and risk of renal cell carcinoma. International Journal of Cancer 2014, 134(11):2699-2706.
134. Mondul A.M., Weinstein S.J., Virtamo J., Albanes D. Influence of vitamin D binding protein on the association between circulating vitamin D and risk of bladder cancer. British Journal of Cancer 2012, 107(9):1589-1594.
135. Morrison N.A., Yeoman R., Kelly P.J., Eisman J.A. Contribution of trans-acting factor alleles to normal physiological variability: Vitamin D receptor gene polymorphism and circulating osteocalcin. Proceedings of the National Academy of Sciences of the United States of America 1992, 89(15):6665-6669.
136. Murtaugh M.A., Sweeney C., Ma K.N., Potter J.D., Caan B.J., Wolff R.K., et al. Vitamin D receptor gene polymorphisms, dietary promotion of insulin resistance, and colon and rectal cancer. Nutrition and Cancer 2006, 55(1):35-43.
137. Muscogiuri G., Sorice G.P., Ajjan R., Mezza T., Pilz S., Prioletta A., et al. Can vitamin D deficiency cause diabetes and cardiovascular diseases? Present evidence and future perspectives. Nutrition, Metabolism, and Cardiovascular Diseases 2012, 22(2):81-87.
138. Newton-Bishop J.A., Beswick S., Randerson-Moor J., Chang Y.M., Affleck P., Elliott F., et al. Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. Journal of Clinical Oncology 2009, 27(32):5439-5444.
139. Ng K., Sargent D.J., Goldberg R.M., Meyerhardt J.A., Green E.M., Pitot H.C., et al. Vitamin D status in patients with stage IV colorectal cancer: Findings from intergroup trial N9741. Journal of Clinical Oncology 2011, 29(12):1599-1606.
140. Ng K., Wolpin B.M., Meyerhardt J.A., Wu K., Chan A.T., Hollis B.W., et al. Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer. British Journal of Cancer 2009, 101(6):916-923.
141. Obara W., Suzuki Y., Kato K., Tanji S., Konda R., Fujioka T. Vitamin D receptor gene polymorphisms are associated with increased risk and progression of renal cell carcinoma in a Japanese population. International Journal of Urology 2007, 14(6):483-487.
142. Ochs-Balcom H.M., Cicek M.S., Thompson C.L., Tucker T.C., Elston R.C., Plummer S J., et al. Association of vitamin D receptor gene variants, adiposity and colon cancer. Carcinogenesis 2008, 29(9):1788-1793.
143. Ojha R.P., Felini M.J., Fischbach L.A. Vitamin D for cancer prevention: Valid assertion or premature anointment?. The American Journal of Clinical Nutrition 2007, 86(6):1804-1805. author reply 1805-1806.
144. Osborne J.E., Hutchinson P.E. Vitamin D and systemic cancer: Is this relevant to malignant melanoma?. The British Journal of Dermatology 2002, 147(2):197-213.
145. Pardanani A., Drake M.T., Finke C., Lasho T.L., Rozell S.A., Jimma T., et al. Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: Clinical correlates and prognostic studies. American Journal of Hematology 2011, 86(12):1013-1016.
146. Pena-Chilet M., Ibarrola-Villava M., Martin-Gonzalez M., Feito M., Gomez-Fernandez C., Planelles D., et al. rs12512631 on the group specific complement (vitamin D-binding protein GC) implicated in melanoma susceptibility. PLoS One 2013, 8(3):e59607.
147. Penna-Martinez M., Ramos-Lopez E., Stern J., Hinsch N., Hansmann M.L., Selkinski I., et al. Vitamin D receptor polymorphisms in differentiated thyroid carcinoma. Thyroid 2009, 19(6):623-628.
148. Pike J., Feldman D., Glorieux F. Vitamin D 1997, Academic Press, San Diego. 1st ed.
149. Pilz S., Dobnig H., Winklhofer-Roob B., Riedmuller G., Fischer J.E., Seelhorst U., et al. Low serum levels of 25-hydroxyvitamin D predict fatal cancer in patients referred to coronary angiography. Cancer Epidemiology, Biomarkers & Prevention 2008, 17(5):1228-1233.
150. Pilz S., Kienreich K., Tomaschitz A., Ritz E., Lerchbaum E., Obermayer-Pietsch B., et al. Vitamin D and cancer mortality: Systematic review of prospective epidemiological studies. Anti-Cancer Agents in Medicinal Chemistry 2013, 13(1):107-117.
151. Pilz S., Tomaschitz A., Drechsler C., Dekker J.M., Marz W. Vitamin D deficiency and myocardial diseases. Molecular Nutrition & Food Research 2010, 54(8):1103-1113.
152. Pilz S., Tomaschitz A., Drechsler C., Zittermann A., Dekker J.M., Marz W. Vitamin D supplementation: A promising approach for the prevention and treatment of strokes. Current Drug Targets 2011, 12(1):88-96.
153. Pilz S., Tomaschitz A., Marz W., Drechsler C., Ritz E., Zittermann A., et al. Vitamin D, cardiovascular disease and mortality. Clinical Endocrinology 2011, 75(5):575-584.
154. Pilz S., Tomaschitz A., Obermayer-Pietsch B., Dobnig H., Pieber T.R. Epidemiology of vitamin D insufficiency and cancer mortality. Anticancer Research 2009, 29(9):3699-3704.
155. Pinczewski J., Slominski A. The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms. Experimental Dermatology 2010, 19(10):860-864.
156. Poole K.E., Loveridge N., Barker P.J., Halsall D.J., Rose C., Reeve J., et al. Reduced vitamin D in acute stroke. Stroke 2006, 37(1):243-245.
157. Powe C.E., Evans M.K., Wenger J., Zonderman A.B., Berg A.H., Nalls M., et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. The New England Journal of Medicine 2013, 369(21):1991-2000.
158. Poynter J.N., Jacobs E.T., Figueiredo J.C., Lee W.H., Conti D.V., Campbell P.T., et al. Genetic variation in the vitamin D receptor (VDR) and the vitamin D-binding protein (GC) and risk for colorectal cancer: Results from the colon cancer family registry. Cancer Epidemiology, Biomarkers & Prevention 2010, 19(2):525-536.
159. Purdue M.P., Hartge P., Davis S., Cerhan J.R., Colt J.S., Cozen W., et al. Sun exposure, vitamin D receptor gene polymorphisms and risk of non-Hodgkin lymphoma. Cancer Causes & Control 2007, 18(9):989-999.
160. Purdue M.P., Lan Q., Kricker A., Vajdic C.M., Rothman N., Armstrong B.K. Vitamin D receptor gene polymorphisms and risk of non-Hodgkin's lymphoma. Haematologica 2007, 92(8):1145-1146.
161. Raimondi S., Johansson H., Maisonneuve P., Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009, 30(7):1170-1180.
162. Raimondi S., Pasquali E., Gnagnarella P., Serrano D., Disalvatore D., Johansson H.A., et al. BsmI polymorphism of vitamin D receptor gene and cancer risk: A comprehensive meta-analysis. Mutation Research 2014, 769:17-34.
163. Randerson-Moor J.A., Taylor J.C., Elliott F., Chang Y.M., Beswick S., Kukalizch K., et al. Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. European Journal of Cancer (Oxford, England: 1990) 2009, 45(18):3271-3281.
164. Ren C., Qiu M.Z., Wang D.S., Luo H.Y., Zhang D.S., Wang Z.Q., et al. Prognostic effects of 25-hydroxyvitamin D levels in gastric cancer. Journal of Translational Medicine 2012, 10. 16-5876-10-16.
165. Saliba W., Barnett O., Rennert H.S., Rennert G. The risk of all-cause mortality is inversely related to serum 25(OH)D levels. The Journal of Clinical Endocrinology and Metabolism 2012, 97(8):2792-2798.
166. Sarkissyan M., Wu Y., Chen Z., Mishra D.K., Sarkissyan S., Giannikopoulos I., et al. Vitamin D receptor FokI gene polymorphisms may be associated with colorectal cancer among African American and hispanic participants. Cancer 2014, 120(9):1387-1393.
167. Schabas R. Artifact in the control group undermines the conclusions of a vitamin D and cancer study. The American Journal of Clinical Nutrition 2008, 87(3):792. author reply 793-794.
168. Schottker B., Jorde R., Peasey A., Thorand B., Jansen E.H., Groot L., et al. Vitamin D and mortality: Meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. BMJ (Clinical Research Ed.) 2014, 348:g3656.
169. Schwalfenberg G.K. A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency. Molecular Nutrition & Food Research 2011, 55(1):96-108.
170. Scragg R. Seasonality of cardiovascular disease mortality and the possible protective effect of ultra-violet radiation. International Journal of Epidemiology 1981, 10(4):337-341.
171. Semba R.D., Houston D.K., Bandinelli S., Sun K., Cherubini A., Cappola A.R., et al. Relationship of 25-hydroxyvitamin D with all-cause and cardiovascular disease mortality in older community-dwelling adults. European Journal of Clinical Nutrition 2010, 64(2):203-209.
172. Serrano D., Gnagnarella P., Raimondi S., Gandini S. Meta-analysis on vitamin D receptor and cancer risk: Focus on the role of TaqI, ApaI, and Cdx2 polymorphisms. European Journal of Cancer Prevention 2015, Epub ahead of print.
173. Shafia S., Qasim I., Aziz S.A., Bhat I.A., Nisar S., Shah Z.A. Role of vitamin D receptor (VDR) polymorphisms in susceptibility to multiple myeloma in ethnic kashmiri population. Blood Cells, Molecules & Diseases 2013, 51(1):56-60.
174. Shahbazi S., Alavi S., Majidzadeh-A K., Ghaffarpour M., Soleimani A., Mahdian R. BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer. Medical Oncology (Northwood, London, England) 2013, 30(1). 393-012-0393-7. Epub 2013 Jan 1.
175. Shanafelt T.D., Drake M.T., Maurer M.J., Allmer C., Rabe K.G., Slager S.L., et al. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood 2011, 117(5):1492-1498.
176. Shui I.M., Mucci L.A., Kraft P., Tamimi R.M., Lindstrom S., Penney K.L., et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: A prospective nested case-control study. Journal of the National Cancer Institute 2012, 104(9):690-699.
177. Sinotte M., Diorio C., Berube S., Pollak M., Brisson J. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. The American Journal of Clinical Nutrition 2009, 89(2):634-640.
178. Sinotte M., Rousseau F., Ayotte P., Dewailly E., Diorio C., Giguere Y., et al. Vitamin D receptor polymorphisms (FokI, BsmI) and breast cancer risk: Association replication in two case-control studies within French Canadian population. Endocrine Related Cancer 2008, 15(4):975-983.
179. Slatter M.L., Yakumo K., Hoffman M., Neuhausen S. Variants of the VDR gene and risk of colon cancer (United States). Cancer Causes & Control 2001, 12(4):359-364.
180. Slattery M.L., Wolff R.K., Curtin K., Fitzpatrick F., Herrick J., Potter J.D., et al. Colon tumor mutations and epigenetic changes associated with genetic polymorphism: Insight into disease pathways. Mutation Research 2009, 660(1-2):12-21.
181. Slominski A., Tobin D.J., Shibahara S., Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiological Reviews 2004, 84(4):1155-1228.
182. Smedby K.E., Eloranta S., Duvefelt K., Melbye M., Humphreys K., Hjalgrim H., et al. Vitamin D receptor genotypes, ultraviolet radiation exposure, and risk of non-Hodgkin lymphoma. American Journal of Epidemiology 2011, 173(1):48-54.
183. Sood M.M., Sood A.R. Dietary vitamin D and decreases in cancer rates: Canada as the national experiment. The American Journal of Clinical Nutrition 2007, 86(5):1549. author reply 1549-1550.
184. Souberbielle J.C., Body J.J., Lappe J.M., Plebani M., Shoenfeld Y., Wang T.J., et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmunity Reviews 2010, 9(11):709-715.
185. Speeckaert M., Huang G., Delanghe J.R., Taes Y.E. Biological and clinical aspects of the vitamin D binding protein (gc-globulin) and its polymorphism. Clinica Chimica Acta 2006, 372(1-2):33-42.
186. Szendroi A., Speer G., Tabak A., Kosa J.P., Nyirady P., Majoros A., et al. The role of vitamin D, estrogen, calcium sensing receptor genotypes and serum calcium in the pathogenesis of prostate cancer. The Canadian Journal of Urology 2011, 18(3):5710-5716.
187. Tang C., Chen N., Wu M., Yuan H., Du Y. Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: A meta-analysis. Breast Cancer Research and Treatment 2009, 117(2):391-399.
188. Tang J.Y., Fu T., Lau C., Oh D.H., Bikle D.D., Asgari M.M. Vitamin D in cutaneous carcinogenesis: Part I. Journal of the American Academy of Dermatology 2012, 67(5). 803.e1-12, quiz 815-816.
189. Theodoratou E., Farrington S.M., Tenesa A., McNeill G., Cetnarskyj R., Barnetson R.A., et al. Modification of the inverse association between dietary vitamin D intake and colorectal cancer risk by a FokI variant supports a chemoprotective action of vitamin D intake mediated through VDR binding. International Journal of Cancer 2008, 123(9):2170-2179.
190. Tjellesen L., Christiansen C. Vitamin D metabolites in normal subjects during one year. A longitudinal study. Scandinavian Journal of Clinical and Laboratory Investigation 1983, 43(1):85-89.
191. Toptas B., Kafadar A.M., Cacina C., Turan S., Yurdum L.M., Yigitbasi N., et al. The vitamin D receptor (VDR) gene polymorphisms in Turkish brain cancer patients. BioMed Research International 2013, 2013:295791.
192. Torkko K.C., van Bokhoven A., Mai P., Beuten J., Balic I., Byers T.E., et al. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-hispanic white and Hispanic white men. Clinical Cancer Research 2008, 14(10):3223-3229.
193. Touvier M., Chan D.S., Lau R., Aune D., Vieira R., Greenwood D.C., et al. Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiology, Biomarkers & Prevention 2011, 20(5):1003-1016.
194. Tretli S., Hernes E., Berg J.P., Hestvik U.E., Robsahm T.E. Association between serum 25(OH)D and death from prostate cancer. British Journal of Cancer 2009, 100(3):450-454.
195. Tretli S., Schwartz G.G., Torjesen P.A., Robsahm T.E. Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: A population-based study. Cancer Causes & Control 2012, 23(2):363-370.
196. Trivedi D.P., Doll R., Khaw K.T. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial. BMJ (Clinical Research Ed.) 2003, 326(7387):469.
197. Tworoger S.S., Gates M.A., Lee I.M., Buring J.E., Titus-Ernstoff L., Cramer D., et al. Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies. Cancer Research 2009, 69(5):1885-1891.
198. Uitterlinden A.G., Fang Y., van Meurs J.B., van Leeuwen H., Pols H.A. Vitamin D receptor gene polymorphisms in relation to vitamin D related disease states. The Journal of Steroid Biochemistry and Molecular Biology 2004, 89-90(1-5):187-193.
199. Vrieling A., Hein R., Abbas S., Schneeweiss A., Flesch-Janys D., Chang-Claude J. Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: A prospective patient cohort study. Breast Cancer Research 2011, 13(4):R74.
200. Wactawski-Wende J., Kotchen J.M., Anderson G.L., Assaf A.R., Brunner R.L., O'Sullivan M.J., et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. The New England Journal of Medicine 2006, 354(7):684-696.
201. Wang J., Eliassen A.H., Spiegelman D., Willett W.C., Hankinson S.E. Plasma free 25-hydroxyvitamin D, vitamin D binding protein, and risk of breast cancer in the nurses' health study II. Cancer Causes & Control 2014, 25(7):819-827.
202. Wang T.J., Pencina M.J., Booth S.L., Jacques P.F., Ingelsson E., Lanier K., et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117(4):503-511.
203. Wang T.J., Zhang F., Richards J.B., Kestenbaum B., van Meurs J.B., Berry D., et al. Common genetic determinants of vitamin D insufficiency: A genome-wide association study. Lancet 2010, 376(9736):180-188.
204. Weinstein S.J., Mondul A.M., Kopp W., Rager H., Virtamo J., Albanes D. Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer. International Journal of Cancer 2013, 132(12):2940-2947.
205. Weinstein S.J., Purdue M.P., Smith-Warner S.A., Mondul A.M., Black A., Ahn J., et al. Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the prostate, lung, colorectal and ovarian cancer screening trial. International Journal of Cancer 2015, 136(6):E654-E664.
206. Whitfield G.K., Remus L.S., Jurutka P.W., Zitzer H., Oza A.K., Dang H.T., et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Molecular and Cellular Endocrinology 2001, 177(1-2):145-159.
207. Wortsman J., Matsuoka L.Y., Chen T.C., Lu Z., Holick M.F. Decreased bioavailability of vitamin D in obesity. The American Journal of Clinical Nutrition 2000, 72(3):690-693.
208. Yin L., Grandi N., Raum E., Haug U., Arndt V., Brenner H. Meta-analysis: Circulating vitamin D and ovarian cancer risk. Gynecologic Oncology 2011, 121(2):369-375.
209. Yin L., Ordonez-Mena J.M., Chen T., Schottker B., Arndt V., Brenner H. Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: A systematic review and meta-analysis. Preventive Medicine 2013, 57(6):753-764.
210. Yudoh K., Matsuno H., Kimura T. 1alpha,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma. The Journal of Laboratory and Clinical Medicine 1999, 133(2):120-128.
211. Zhao X.Z., Yang B.H., Yu G.H., Liu S.Z., Yuan Z.Y. Polymorphisms in the vitamin D receptor (VDR) genes and skin cancer risk in european population: A meta-analysis. Archives of Dermatological Research 2014, 306(6):545-553.
212. Zhou W., Heist R.S., Liu G., Asomaning K., Neuberg D.S., Hollis B.W., et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. Journal of Clinical Oncology 2007, 25(5):479-485.
213. Zhou Z.C., Wang J., Cai Z.H., Zhang Q.H., Cai Z.X., Wu J.H. Association between vitamin D receptor gene Cdx2 polymorphism and breast cancer susceptibility. Tumour Biology 2013, 34(6):3437-3441.
214. Zhou L., Zhang X., Chen X., Liu L., Lu C., Tang X., et al. GC Glu416Asp and Thr420Lys polymorphisms contribute to gastrointestinal cancer susceptibility in a Chinese population. International Journal of Clinical and Experimental Medicine 2012, 5(1):72-79.
215. Zittermann A., Iodice S., Pilz S., Grant W.B., Bagnardi V., Gandini S. Vitamin D deficiency and mortality risk in the general population: A meta-analysis of prospective cohort studies. The American Journal of Clinical Nutrition 2012, 95(1):91-100.
216. Zittermann A., Schleithoff S.S., Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. The British Journal of Nutrition 2005, 94(4):483-492.